Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To investigate the 60 month impact of surgery and somatostatin analogues (SSA) on glucose
metabolism in acromegaly we will analyzed data from 100 patients with acromegaly according
with different treatments (group A=with SSA only; group B= SSA followed by surgery; group C=
surgery only; group D= surgery followed by SSA). At diagnosis and after 6-12 and 60 months
were analyzed as primary outcome measure changes in fasting glucose and as secondary outcome
measures changes of glycated hemoglobin (HbA1c) and insulin levels, HOMA-R and HOMA-β,
representing insulin resistance and β-cell function, respectively.
We will enrol 100 patients and expect half of them to have IGT or diabetes mellitus. We do
not expect changes according with different treatment after 60 months while SSA-treated
patients might experience deterioration of glucose tolerance after 6-12 months. We intend to
look for predictors of deterioration of glucose tolerance.